Global Lysosomal Storage Diseases Market to Reach $15.2 Billion by 2030
The global market for Lysosomal Storage Diseases estimated at US$9.8 Billion in the year 2022, is projected to reach a revised size of US$15.2 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2022-2030. Enzyme Replacement Therapy (ERT), one of the segments analyzed in the report, is projected to record 6.1% CAGR and reach US$7.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Substrate Reduction Therapy (SRT) segment is readjusted to a revised 5.4% CAGR for the next 8-year period.The U.S. Market is Estimated at $2.9 Billion, While China is Forecast to Grow at 5.3% CAGR
The Lysosomal Storage Diseases market in the U.S. is estimated at US$2.9 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 5.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 4.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.Select Competitors (Total 44 Featured) -
- Actelion Pharmaceuticals Ltd.
- Alexion Pharmaceuticals, Inc.
- Amicus Therapeutics, Inc.
- BioMarin Pharmaceutical, Inc.
- Chiesi Farmaceutici SpA
- Greenovation Biotech GmbH
- Horizon Pharma PLC
- Leadiant Biosciences SpA
- Mylan NV
- Pfizer, Inc.
- Protalix Biotherapeutics
- Recordati S.p.A.
- Sanofi Genzyme
- Shire PLC
- Synageva BioPharma Corporation
- Valerion Therapeutics, LLC.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Actelion Pharmaceuticals Ltd.
- Alexion Pharmaceuticals, Inc.
- Amicus Therapeutics, Inc.
- BioMarin Pharmaceutical, Inc.
- Chiesi Farmaceutici SpA
- Greenovation Biotech GmbH
- Horizon Pharma PLC
- Leadiant Biosciences SpA
- Mylan NV
- Pfizer, Inc.
- Protalix Biotherapeutics
- Recordati S.p.A.
- Sanofi Genzyme
- Shire PLC
- Synageva BioPharma Corporation
- Valerion Therapeutics, LLC.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 193 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 9.8 Billion |
Forecasted Market Value ( USD | $ 15.2 Billion |
Compound Annual Growth Rate | 5.6% |
Regions Covered | Global |